The Role of Mitochondrial Biogenesis Dysfunction in Diabetic Cardiomyopathy

Biomol Ther (Seoul). 2022 Sep 1;30(5):399-408. doi: 10.4062/biomolther.2021.192. Epub 2022 Apr 12.

Abstract

Diabetic cardiomyopathy (DCM) is described as abnormalities of myocardial structure and function in diabetic patients without other well-established cardiovascular factors. Although multiple pathological mechanisms involving in this unique myocardial disorder, mitochondrial dysfunction may play an important role in its development of DCM. Recently, considerable progresses have suggested that mitochondrial biogenesis is a tightly controlled process initiating mitochondrial generation and maintaining mitochondrial function, appears to be associated with DCM. Nonetheless, an outlook on the mechanisms and clinical relevance of dysfunction in mitochondrial biogenesis among patients with DCM is not completely understood. In this review, hence, we will summarize the role of mitochondrial biogenesis dysfunction in the development of DCM, especially the molecular underlying mechanism concerning the signaling pathways beyond the stimulation and inhibition of mitochondrial biogenesis. Additionally, the evaluations and potential therapeutic strategies regarding mitochondrial biogenesis dysfunction in DCM is also presented.

Keywords: Cardiomyopathy; Diabetes; Diabetic cardiomyopathy; Mitochondrial biogenesis; PGC-1α.

Publication types

  • Review